StockNews.AI
PODD
StockNews.AI
98 days

Insulet Announces Publication of 2024 Sustainability Report

1. Insulet's 2024 Sustainability Report emphasizes strong ESG commitments. 2. The company met 11% of global electricity needs with renewable energy. 3. Installed 5,700 solar panels, powering 21% of its Malaysian facility. 4. Expanded Omnipod access and sustainable product innovations significantly. 5. Launched corporate giving program, enhancing community and employee engagement.

5m saved
Insight
Article

FAQ

Why Bullish?

Insulet's sustainability efforts align with growing investor interest in ESG, potentially attracting new investments. Companies showcasing strong ESG performance, like Tesla, have seen notable stock price growth.

How important is it?

PODD's commitment to sustainability may enhance its market image, appealing to eco-conscious investors and potentially boosting long-term stock performance.

Why Long Term?

Sustainable practices and community involvement may result in a long-term brand loyalty increase, similar to Unilever's success with sustainability initiatives boosting sales over time.

Related Companies

TSLAUNLYABT
- ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, social, and governance (ESG) initiatives. “At Insulet, our sustainability impact is inextricably tied to our mission as a company and our workplace culture. Through our products and innovative business models, we can make life simpler for millions of people with diabetes while improving health outcomes,” said Vice President of Global Sustainability and Chief Sustainability Officer, Lisa Brady. “We remain steadfast in our commitment to creating positive change – for people with diabetes, for our environment, and for our communities.” Key highlights from the 2024 Sustainability Report include: Resilient Operations: Met 11% of annual global electricity needs with renewable energy. Installed more than 5,700 rooftop solar panels at the new manufacturing facility in Malaysia, meeting 21% of the facility's electricity needs after they were brought online. Malaysia facility designed to achieve both Green Building Index (GBI) and Leadership in Energy and Environmental Design (LEED) Silver certifications. Sustainable Product Innovation: Continued the U.S. Pod takeback pilot in Massachusetts and expanded the pilot to California. Accepted 7.4 million Pods through global product takeback programs. Developed a long-term roadmap to create efficient and sustainable packaging. People and Communities: Expanded access to Omnipod 5 internationally and through integration with Abbott's FreeStyle Libre 2 Plus and Dexcom G7 sensors, and in the U.S., we launched the Omnipod 5 App for iPhone. Introduced Insulet’s Ways of Working to empower teams and foster cross functional collaboration while providing exceptional customer and employee experiences. Launched "Insulet for Good," a global corporate giving program, surpassing goals for employee engagement and volunteer hours. The 2024 Sustainability Report can be found on Insulet.com and Investors.Insulet.com/ESG. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com. ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. More News From Insulet Corporation

Related News